Open Access Open Access  Restricted Access Subscription or Fee Access

Opioid regimens in patients with chronic pain with multiple cytochrome P450 defects

Forest Tennant, MD, DrPH


There is a subgroup of patients with chronic pain who have multiple cytochrome P450 enzyme defects. These patients tend to use opioids that are not metabolized by the CYP450 system and most apparently require a higher than average dosage. A significant number require nonoral administration.


opioid, cytochrome, defects

Full Text:



Holmquist GL: Opioid metabolism and effects of cytochrome P450. Pain Med. 2009; 10: S20-S29.

Zhou SF: Polymorphism of human cytochrome P450 and it clinical significance. Clin Pharmacokinet. 2009; 48: 689-723.

Lee CR, Goldstein JA, Pieper JA: Cytochrome P4502C9 polymorphisms: A comprehensive review of the in vitro and data. Pharmacogenetics. 2002; 12: 251-263.

Smith HS: Opioid metabolism. Mayo Clin Proc. 2009; 84(7): 613-624.

Candiotti KA, Zonggi Y, Rodriguez V, et al.: The impact of CYP2D6 genetic polymorphism on postoperative morphine consumption. Pain Med. 2009; 10: 799-805.

Mikus G, Weiss J: Influence of CYP2D6 genetics on opioid kinetics, metabolism and response. Curr Pharmacogenomics. 2005; 3: 43-52.

Hutchinson MR, Menelaou A, Foster DJ, et al.: CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004; 57(3): 287-297.

Heiskanen T, Olkkola KT, Kalso E: Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther. 1998; 64(6): 603-611.

Susce MT, Murray-Carmichael E, de Leon J: Response to hydrocodone, codeine, and oxycodone in a CYP2D6 poor metabolizer. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30: 1356-1358.

Samer CF, Daali Y, Wagner M, et al.: The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol. 2010; 160: 907-918.

Feierman DE, Lasker JM: Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes: Role of CYP3A4. Drug Metab Dispos. 1996; 24(9): 932-939.

Shinderman M, Maxwell S, Browand-Ame M, et al.: Cytochrome P4503A4 metabolic activity, methadone blood concentrations and methadone doses. Drug Alcohol Depend. 2003; 69: 205-211.

Moody DE, Alburges ME, Parker RJ, et al.: The involvement of cytochrome P450 3A4 in the N-demethylation of l-aacetylmethadol (LAAM), norlaam, and methadone. Drug Metab Dispos. 1997; 25: 1347-1353.

Iribarne C, Berthou F, Bairds S, et al.: Involvement of cytochrome P4503A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996; 9: 365-373.

Adams M, Preniaszek HJ, Gammaitoni AR, et al.: Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J Clin Pharmacol. 2005; 45: 337-345.

Paine MF, Hart HL, Ludington SS, et al.: The human intestinal cytochrome P450 “PIE.” Drug Metab Dispos. 2006; 34(5): 880-886.

Zhang QY, Dunbar D, Ostrowel A, et al.: Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos. 1999; 27: 804-812.

Yang J, Tucker GT, Rostami-Hodejan A: Cytochrome P-450 3A4 expression and activity in the human small intestine. Clin Pharmacol Ther. 2004; 76: 391.

Obuch RS, Zhang QY, Dunbar D, et al.: Metabolic characterization of the major human small intestinal cytochrome P-450s. Drug Metab Dispos. 2001; 29: 347-352.

Paine MF, Khalighi M, Fisher JM, et al.: Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther. 1997; 283: 1552-1562.

Paine MF, Schmiedlin-Ren P, Watkins PB: Cytochrome P-4501s expression in human small bowel: Interindividual variation and inhibition by ketoconazole. Drug Metab Dispos. 1999; 27: 360-364.



  • There are currently no refbacks.